Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China flag China · Delayed Price · Currency is CNY
19.89
-0.79 (-3.82%)
Nov 17, 2026, 3:00 PM CST

Nanjing Vazyme Biotech Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
287.45804.9434.251,9671,5451,478
Trading Asset Securities
2,5042,0492,2221,5141,7191,976
Cash & Short-Term Investments
2,7912,8542,6563,4813,2643,454
Cash Growth
2.57%7.45%-23.69%6.65%-5.49%239.50%
Accounts Receivable
495.07460.05483.61351.93839.62322.32
Other Receivables
10.0311.5620.814.077.724.67
Receivables
505.11471.61504.42356.01847.35326.99
Inventory
323.55343.67362.18346.25364.2242.19
Prepaid Expenses
-2.130.05---
Other Current Assets
37.8636.1448.5847.1289.7128.1
Total Current Assets
3,6583,7083,5714,2304,5654,051
Property, Plant & Equipment
564.14617.48726.07767.3679.48308.98
Long-Term Investments
89.0779.9654.8347.322.3118.48
Goodwill
130.49130.49130.49130.49130.49-
Other Intangible Assets
75.7986.6395.19101.2449.716.65
Long-Term Accounts Receivable
0.360.060.15---
Long-Term Deferred Tax Assets
186.01166.62146.04106.5167.1224.87
Long-Term Deferred Charges
182.55220.12278.91280.54318.31145
Other Long-Term Assets
16.111945.5182.53172.6942.25
Total Assets
4,9025,0285,0495,7466,0054,607

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
105.5391.5990.4146.82318.78118.76
Accrued Expenses
115.42142.43129.74112.52258.07104.7
Short-Term Debt
716.83686.68551.321,134272.21-
Current Portion of Leases
42.5828.4357.0346.1658.2531.25
Current Income Taxes Payable
33.872.230.60.030.5420.02
Current Unearned Revenue
63.1572.1454.8755.92214.5595.03
Other Current Liabilities
11.2518.3619.3624.0931.6717.5
Total Current Liabilities
1,0891,042903.331,5201,154387.26
Long-Term Leases
97.5127.33143.36106.89127.6859.93
Long-Term Unearned Revenue
70.261.7648.3821.3819.2516.24
Long-Term Deferred Tax Liabilities
1.461.031.261.5111.190.87
Other Long-Term Liabilities
4.794.758.7267.680.9215.52
Total Liabilities
1,2631,2371,1051,7171,393479.83

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
516.99397.73402.13400.01400.01400.01
Additional Paid-In Capital
2,2242,3392,5122,4422,4292,422
Retained Earnings
888.261,0631,1391,2091,7801,305
Treasury Stock
-5.01-3-104.4-20.01--
Comprehensive Income & Other
-0.68-0.63-3.97-1.72--
Total Common Equity
3,6233,7963,9454,0294,6094,127
Minority Interest
16.54-4.82-1.63-0.113.2-
Shareholders' Equity
3,6403,7913,9444,0294,6124,127
Total Liabilities & Equity
4,9025,0285,0495,7466,0054,607

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
856.9842.44751.711,287458.1491.18
Net Cash (Debt)
1,9342,0121,9052,1942,8063,362
Net Cash Growth
4.00%5.62%-13.19%-21.81%-16.56%230.91%
Net Cash Per Share
2.953.734.054.285.417.13
Filing Date Shares Outstanding
516.99517.05517.16516.1520.01520.01
Total Common Shares Outstanding
516.99517.05517.16516.1520.01520.01
Working Capital
2,5692,6662,6682,7113,4113,664
Book Value Per Share
7.017.347.637.818.867.94
Tangible Book Value
3,4173,5793,7203,7984,4294,111
Tangible Book Value Per Share
6.616.927.197.368.527.90
Machinery
-720.6712.88656.11513.97250.31
Construction In Progress
-63.8669.42127.4869.44-